Biblio Discovery — Demo Discovery Service

39 results for "Mark Litzow"

Showing 1–20 · 0.98 seconds · RSS

  1. Journal Article

    The use of haploidentical stem cell transplant as an alternative donor source in patients with decreased access to matched unrelated donors

    Christopher Graham; Mark Litzow

    Hematology, Vol. 29 No. 1 · 2024 · English · DOAJ Scopus

    Introduction The likelihood of finding HLA-matched unrelated donors for rare HLA types and non-white European ancestry continues to be a challenge with less than a 70% chance of finding a full match. Mismatched transplants continue to have high rates of transplant-related mortality. With the…

  2. Journal Article

    Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor

    Naseema Gangat; Kebede H. Begna; Aref Al-Kali et al.

    Blood Cancer Journal, Vol. 13 No. 1 · 2023 · English · DOAJ Scopus

    Abstract Between October 2007 and July 2013, 183 Mayo Clinic patients (median age 65 years; 58% males) with high/intermediate risk myelofibrosis (MF) were enrolled in consecutive phase 1/2 JAK2 inhibitor (JAKi) clinical trials with momelotinib (n = 79), ruxolitinib (n = 50), fedratinib (n = 23) and…

  3. Journal Article Full text

    Less intensive antileukemic therapies (monotherapy and/or combination) for older adults with acute myeloid leukemia who are not candidates for intensive antileukemic therapy: A systematic review and meta-analysis

    Luis Enrique Colunga-Lozano; Fernando Kenji Nampo; Arnav Agarwal et al.

    PLOS ONE, Vol. 17 No. 2 · 2022 · English · PLOS Scopus

    Introduction: Elderly patients with acute myeloid leukemia not eligible for intensive antileukemic therapy are treated with less intensive therapies, uncertainty remains regarding their relative merits. Objectives: To compare the effectiveness and safety of less intensive antileukemic therapies for…

    Also available at: DOAJ

  4. Journal Article

    Immune-Mediated Autonomic Neuropathies following Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia

    Abhishek Mangaonkar; Hassan Al Khateeb; Narjust Duma et al.

    Case Reports in Hematology, Vol. 2017 · 2017 · English · DOAJ

    Background/Aims. Autonomic dysfunction (AD) after allogeneic stem cell transplant (SCT) is a rare occurrence and likely immune-mediated in etiology. There is limited literature on this topic and hence, we wish to briefly describe management of two cases at our institution and their outcomes…

  5. Journal Article

    A novel Iowa–Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction

    Kalyan Nadiminti; Kimberly Langer; Ehsan Shabbir et al.

    Blood Cancer Journal, Vol. 11 No. 11 · 2021 · English · DOAJ Scopus

    Abstract Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative option for many hematologic conditions and is associated with considerable morbidity and mortality. Therefore, prognostic tools are essential to navigate the complex patient, disease, donor, and transplant…

  6. Journal Article

    Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia

    Nicola Gökbuget; Hagop M. Kantarjian; Monika Brüggemann et al.

    Blood Advances, Vol. 3 No. 20 · 2019 · English · DOAJ Scopus

    Abstract: Minimal residual disease (MRD), where leukemic cell levels are lower than the morphologic detection threshold, is the most important prognostic factor for acute lymphoblastic leukemia (ALL) relapse during first-line chemotherapy treatment and is standard of care in treatment monitoring…

  7. Journal Article

    A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia

    Guru Subramanian Guru Murthy; Antoine N. Saliba; Aniko Szabo et al.

    Haematologica, Vol. 999 No. 1 · 2024 · English · DOAJ Scopus

    Azacitidine/venetoclax is an active regimen in patients with newly diagnosed AML. However, primary or secondary resistance to azacitidine/venetoclax is an area of unmet need and overexpression of MCL-1 is suggested to be a potential resistance mechanism. Pevonedistat inhibits MCL-1 through…